ALAS1 and anhaptoglobinemia: An investigational RNA interference therapeutic, givosiran, that specifically targets ALAS1 in hepatocytes has been recently approved for the treatment of AHP in adults (in the US and Brazil) or in patients who are older than 12 years (in Europe) [49–51].